Funding for this research was provided by:
Volkswagen Foundation (90 087-1, 92 087)
Deutsche Forschungsgemeinschaft (TRR241-A05)
Deutsche Forschungsgemeinschaft (INST 335/597-1, INST 335/597-1, TRR241-B01, CRC1340, CRC1449)
Charité - Universitätsmedizin Berlin
Received: 10 February 2022
Accepted: 31 May 2022
First Online: 13 June 2022
: The study was approved by the ethics committee of Charité-Universtitätsmedizin Berlin (EA4/117/21).
: Written informed consent was obtained from the patient and included the consent to publish clinical information.
: B.S. has served as consultant for Abbvie, Arena, BMS, Boehringer, Celgene, Falk, Galapagos, Janssen, Lilly, Pfizer, Prometheus and Takeda and received speaker’s fees from Abbvie, CED Service GmbH, Falk, Ferring, Janssen, Novartis, Pfizer, Takeda [payments were made to the institution]. A.N.H, J.K., T.S., S.S., S.T., S.A., U.K. declare no conflict of interest.